Trial Profile
A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Tolcapone (Primary) ; Oxaliplatin
- Indications Neuroblastoma; Parkinson's disease
- Focus Adverse reactions
- 22 Jul 2019 According to the trial , the study is focusing on the effect of investigational drug on neuroblastoma, I have indexed it as an indication. The RDI mentiones the active development of the drug for Parkinson's hence retained it into the patient segment. Please update furtherdisease
- 17 Jul 2019 Status changed from recruiting to discontinued.
- 16 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.